Table 3.
Analyses of prognostic factors for survival before and after PSM and sIPTW analyses
| Variable | Crude cohort | PSM | sIPTW | |||||||||
| Univariate analysis | Multivariate analysis | Univariate analysis | Multivariate analysis | Univariate analysis | Multivariate analysis | |||||||
| HR (95% CI) | P value | HR (95% CI) | P value | HR (95% CI) | P value | HR (95% CI) | P value | HR (95% CI) | P value | HR (95% CI) | P value | |
| Age | 1.03 (0.67–1.58) | 0.899 | 0.83 (0.46–1.51) | 0.547 | 0.95 (0.61–1.50) | 0.841 | ||||||
| Sex | 0.87 (0.47–1.59) | 0.641 | 0.95 (0.37–2.42) | 0.917 | 0.83 (0.50–1.40) | 0.492 | ||||||
| Child-Pugh classification = B | 0.98 (0.54–1.75) | 0.936 | 0.66 (0.2–2.22) | 0.505 | 0.91 (0.55–1.48) | 0.620 | ||||||
| Metastasis | 0.94 (0.63–1.4) | 0.768 | 0.98 (0.57–1.7) | 0.946 | 0.98 (0.57–1.7) | 0.963 | ||||||
| PVTT type II | 2.73 (1.6–4.68) | 0.000 | 2.49 (1.41–4.39) | 0.001 | 2.72 (1.14–6.5) | 0.025 | 2.91 (1.22–6.98) | 0.017 | 2.97 (1.64–5.37) | 0.000 | 2.81 (1.67–4.82) | 0.000 |
| PVTT type III | 7.18 (3.9–13.2) | 0.000 | 7.97 (3.96–16.03) | 0.000 | 5.5 (2.46–12.31) | 0.000 | 6.51 (2.47–17.14) | 0.001 | 9.21 (4.41–19.24) | 0.000 | 8.88 (3.91–20.18) | 0.000 |
| AFP ≥400 ng/mL | 2.91 (1.91–4.45) | 0.000 | 1.69 (1.07–2.68) | 0.025 | 2.61 (1.47–4.64) | 0.001 | 1.93 (1.00–3.73) | 0.049 | 2.84 (1.74–4.65) | 0.000 | 1.77 (1.06–2.96) | 0.028 |
| HBV | 1.07 (0.71–1.61) | 0.758 | 1.31 (0.74–2.33) | 0.358 | 1.30 (0.77–2.19) | 0.334 | ||||||
| ECOG = 1 | 0.75 (0.47–1.2) | 0.231 | 0.79 (0.42–1.5) | 0.473 | 0.84 (0.53–134) | 0.461 | ||||||
| TBIL | 1.01 (0.99–1.03) | 0.344 | 1.02 (0.99–1.05) | 0.118 | 1.02 (0.99–1.04) | 0.146 | ||||||
| ALB | 1.01 (0.97–1.04) | 0.682 | 1.01 (0.97–1.06) | 0.556 | 1.03 (0.98–1.08) | 0.222 | ||||||
| ALT | 1 (1–1) | 0.810 | 1.01 (0.99–1.03) | 0.159 | 0.99 (0.99–1.00) | 0.864 | ||||||
| Cr | 1 (0.98–1.01) | 0.815 | 1 (0.97–1.03) | 0.801 | 0.99 (0.98–1.01) | 0.945 | ||||||
| Size | 1 (1–1.01) | 0.410 | 1 (0.99–1.01) | 0.624 | 1.00 (0.99–1.00) | 0.340 | ||||||
| Tumor number = 2 | 2.2 (1.13–4.29) | 0.021 | 1.83 (0.92–3.64) | 0.084 | 1.56 (0.63–3.84) | 0.337 | 1.54 (0.85–2.78) | 0.158 | 1.38 (0.75–2.55) | 0.298 | ||
| Tumor number ≥3 | 2.98 (1.48–6.01) | 0.002 | 2.38 (1.15–4.91) | 0.019 | 1.98 (0.79–4.96) | 0.145 | 2.41 (1.38–4.18) | 0.002 | 2.07 (1.17–3.71) | 0.014 | ||
| TACE | 1.09 (0.94–1.28) | 0.261 | 1.03 (0.82–1.29) | 0.805 | 1.11 (0.96–1.28) | 0.176 | ||||||
| Treatment | 0.47 (0.3–0.73) | 0.001 | 0.42 (0.26–0.68) | 0.000 | 0.44 (0.24–0.82) | 0.010 | 0.29 (0.15–0.57) | 0.000 | 0.48 (0.27–0.88) | 0.017 | 0.43 (0.24–0.76) | 0.004 |
ALB, albumin; ALT, alanine aminotransferase; AFP, alpha-fetoprotein; CI, confidence interval; Cr, creatinine; ECOG, Eastern Cooperative Oncology Group; HR, hazard ratio; HBV, hepatitis B virus; PSM, propensity score matching; PVTT, portal vein tumor thrombus; sIPTW, stabilized inverse probability of treatment weighting; SMD, standardized mean differences; TACE, transarterial chemoembolization; TACE-A, TACE combined with apatinib; TACE-AP, TACE combined with apatinib and PD-1 inhibitors; TBIL, total bilirubin.